Lee, J. Et Al. 2005. Intrapatient dose escalation to 800 mg/m(2) pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy.. 41st Annual Meeting of the American-Society-of-Clinical-Oncology , (Florida, United States Of America).

Lee, J., Hsia, T., Yang, C., Heo, D., Chang, G., Park, K., ... Kim, S.(2005). Intrapatient dose escalation to 800 mg/m(2) pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy. . 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America

Lee, JS Et Al. "Intrapatient dose escalation to 800 mg/m(2) pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy.," 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 2005

Lee, JS Et Al. "Intrapatient dose escalation to 800 mg/m(2) pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy.." 41st Annual Meeting of the American-Society-of-Clinical-Oncology , Florida, United States Of America, 2005

Lee, J. Et Al. (2005) . "Intrapatient dose escalation to 800 mg/m(2) pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy.." 41st Annual Meeting of the American-Society-of-Clinical-Oncology , Florida, United States Of America.

@conferencepaper{conferencepaper, author={JS Lee Et Al. }, title={Intrapatient dose escalation to 800 mg/m(2) pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy.}, congress name={41st Annual Meeting of the American-Society-of-Clinical-Oncology}, city={Florida}, country={United States Of America}, year={2005}}